focal segmental glomerulosclerosis: genetic analysis and target therapy

Clicks: 259
ID: 187055
2018
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #21 of 39 articles by views in oncology letters

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
With focal segmental glomerulosclerosis (FSGS) is associated with initial damage of podocytes. Human genetic studies over the last few years have shown that FSGS is primarily a podocytopathia with more than 20 mutated genes involved in the pathogenesis of this disease. Nephrin (NPHS1 gene) together with the podocine (NPHS2 gene) are the main proteins of podocyts slit diaphragm. Autosomal-recessive mutations of NPHS1, NPHS2 are associated with more severe condition of patients, which is manifested by early proteinuria and end-stage renal disease compared with autosomal-dominant mutations of INF2, TRPC6 and ACTN4. For initial treatment of FSGS, Kidney Disease Improving Global Outcomes (KDIGO) 2012 recommends the use of corticosteroid and immunosuppressive therapy.
Reference Key
melnyk2018pokifocal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;O.O. Melnyk
Journal oncology letters
Year 2018
DOI
10.22141/2307-1257.7.1.2018.122218
URL
http://kidneys.zaslavsky.com.ua/article/view/122218
Keywords
focal segmental glomerulosclerosis podocytes urology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.